GO Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- GO Therapeutics's estimated annual revenue is currently $1.7M per year.
- GO Therapeutics's estimated revenue per employee is $155,000
Employee Data
- GO Therapeutics has 11 Employees.
- GO Therapeutics grew their employee count by -15% last year.
GO Therapeutics's People
| Name | Title | Email/Phone |
|---|
GO Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is GO Therapeutics?
GO Therapeutics is exploiting unique aspects of cancer cell biology to develop a new class of cancer therapies for previously intractable solid tumors. We target O-linked glycoproteins specific to cancer cells to develop proprietary, high-affinity antibodies to novel cancer-specific targets. Our antibodies are the basis for a broad array of potent cancer-killing modalities including T-cell bispecifics (TCBs), CAR-T, and antibody drug conjugates (ADCs). Each are designed to kill cancer while sparing healthy tissue.
keywords:N/A
N/A
Total Funding
11
Number of Employees
$1.7M
Revenue (est)
-15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Natick
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1M | 11 | 57% | N/A |
#2 | $1M | 12 | 0% | N/A |
#3 | $2M | 13 | 8% | N/A |
#4 | $1M | 13 | 8% | N/A |
#5 | $2M | 15 | 0% | N/A |